Contact
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
Key regions: United States, China, Germany, Japan, Europe
Equatorial Guinea, a small country located in West Africa, has a developing pharmaceuticals market that is driven by various factors.
Customer preferences: The customers in Equatorial Guinea prefer generic drugs due to their affordability. The majority of the population is not covered by health insurance, and thus, they have to pay for their medical expenses out of pocket. Therefore, the demand for cheaper drugs is high, and generic drugs fulfill this demand.
Trends in the market: The pharmaceuticals market in Equatorial Guinea is growing due to the increasing prevalence of diseases such as malaria, HIV/AIDS, and tuberculosis. The government has implemented various healthcare programs to tackle these diseases, which has led to an increase in demand for drugs. Additionally, the government has also increased its healthcare spending, which has further fueled the growth of the pharmaceuticals market.
Local special circumstances: The pharmaceuticals market in Equatorial Guinea is heavily regulated by the government. The government controls the importation, distribution, and sale of drugs in the country. This has led to a limited number of pharmaceutical companies operating in the country. Additionally, the country has a small population, which limits the potential market size for pharmaceutical companies.
Underlying macroeconomic factors: Equatorial Guinea has a growing economy, which has led to an increase in disposable income. This has resulted in an increase in healthcare spending, which has further fueled the growth of the pharmaceuticals market. Additionally, the government has implemented policies to attract foreign investment, which has led to an increase in the number of pharmaceutical companies operating in the country. In conclusion, the pharmaceuticals market in Equatorial Guinea is developing due to the increasing prevalence of diseases, government healthcare programs, and an increase in healthcare spending. However, the market is limited by government regulations and a small population size.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)